Palo Alto-based cancer test developer Guardant Health cuts 130 jobs


The move comes about a month after the company's stock dropped by about 30% when it reported trial results of a test for colorectal cancer that disappointed some of its investors.

Previous T. Rowe Price, pummeled by market downturn, lost nearly a quarter of assets in 2022
Next Polis continues health care reform push, risks clash with providers